Evidence map›Paper›PMID 40487540›Full record

ArticleTherapeutic advances in musculoskeletal disease2025

Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab.

Jan Brandt-Jürgens, Martin Rudwaleit, Frank Behrens, Christopher Ritchlin, Daniel Peterlik, Erhard Quebe-Fehling, Atul Deodhar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in musculoskeletal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jan Brandt-JürgensRheumatologische Schwerpunktpraxis, Bundesallee 104/105, 12161 Berlin, Germany.
Martin RudwaleitInternal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, University of Bielefeld, Bielefeld, Germany.
Frank BehrensRheumatology University Hospital and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Goethe University, Frankfurt, Germany.
Christopher RitchlinAllergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, NY, USA.
Daniel PeterlikNovartis Pharma GmbH, Nürnberg, Germany.
Erhard Quebe-FehlingNovartis Pharma AG, Basel, Switzerland.
Atul DeodharDivision of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported. Objective: To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies. Design: This was a post hoc analysis from 11 phase III studies. Methods: Pooled data from axSpA (MEASURE 1-5 and PREVENT studies) and PsA (FUTURE 1-5 studies) were analyzed. Results: In the axSpA cohort ( Conclusion: During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.

Indexed as

axial spondyloarthritisinterleukin-17Aphase III studypsoriatic arthritisuveitis

Identifiers

PMID40487540
PMCPMC12144362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.